The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study
Abstract
BACKGROUND: Lipodystrophy, dyslipidaemia and insulin resistance often complicate protease inhibitor-containing antiretroviral therapy. The aims of this study were to determine if these are reversible with continued HIV suppression following protease inhibitor substitution. METHODS: Eighty-one HIV protease inhibitor recipients (78 male; mean antiretroviral therapy, 55 months) with predominant peripheral lipoatrophy, HIV RNA < 400 copies/ml plasma for at least the preceding 6 months, and no prior abacavir, non-nucleoside analogue or adefovir therapy were randomized 3 : 2 to continue nucleoside analogues and substitute protease inhibitor(s) with abacavir, nevirapine, adefovir and hydroxyurea (n = 49) or to continue all therapy (n = 32) with an option to switch at week 24. The primary endpoints were total body fat and HIV RNA at week 24. Other assessments were regimen safety, regional body composition, metabolic parameters, quality of life, and CD4 T-lymphocyte counts to week 48. RESULTS: There was a greater decline in total body fat in the switch group than in the continue group (-1.6 and -0.4 kg, respectively at week 24; P = 0.006). This comprised greater declines in limb and subcutaneous abdominal fat, and in intra-abdominal fat of patients with moderate or severe abdominal fat accumulation. Viral suppression was similar, despite 18 (37%) switch group patients ceasing at least one study drug by week 24 because of adverse events. Total cholesterol and triglycerides declined more in the switch group (both P < 0.002). High density lipoprotein cholesterol increased significantly in both groups at week 48 (P < 0.02). There was no change for any glycaemic parameter. CONCLUSIONS: In predominantly lipoatrophic patients, switching from HIV protease inhibitor therapy lead to improved lipids and less intra-abdominal fat, but also to less peripheral fat, and had minimal effect on insulin resistance. Virological control in these heavily pretreated patients was unaffected, despite frequent switch drug cessations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., & Goldstein, J. L. (1999) · Nature · doi:10.1038/43448 · Cited by 1,038
Walli, R., Herfort, O., Michl, G. M., Demant, T., Jäger, H., Dieterle, C., Bogner, J. R., Landgraf, R., & Goebel, F. D. (1998) · AIDS · doi:10.1097/00002030-199815000-00001 · Cited by 519
Metformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial
Hadigan, C., Corcoran, C., Basgoz, N., Davis, B., Sax, P., & Grinspoon, S. (2000) · JAMA · doi:10.1001/jama.284.4.472 · Cited by 357
Cited by
Acquired and Inherited Lipodystrophies
Garg, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra025261 · Cited by 941
Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., Glesby, M. J., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378131 · Cited by 580
Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
Self-citationValantin, M.-A., Aubron-Olivier, C., Ghosn, J., Laglenne, E., Pauchard, M., Schoen, H., Bousquet, R., Katz, P., Costagliola, D., & Katlama, C. (2003) · AIDS · doi:10.1097/00002030-200311210-00009 · Cited by 355
HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management
Carr, A. (2003) · AIDS · doi:10.1097/00002030-200304001-00017 · Cited by 275
Self-citation
Metadata
- Authors
- Carr, A., Hudson, J., Chuah, J., Mallal, S., Law, M., Hoy, J., Doong, N., French, M., Smith, D., & Cooper, D. A.
- Venue
- AIDS
- Published
- 2001-09
- Volume
- 15
- Issue
- 14
- Pages
- 1811-1822
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2070362389
- Cited by
- 172
- References
- 4
- FWCI
- 30.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. https://app.cochat.ai/papers/10.1097/00002030-200109280-00010
- The paper
- Carr, A., Hudson, J., Chuah, J., Mallal, S., Law, M., Hoy, J., Doong, N., French, M., Smith, D., & Cooper, D. A. (2001). HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. https://doi.org/10.1097/00002030-200109280-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.